| 產(chǎn)品描述： | CNX-774 is an orally active, irreversible and selective BTK inhibitor, with an IC50 of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification |
| 靶點： |
IC50: 1 nM (BTK);BTK |
| 體內(nèi)研究： |
CNX-774 is stable and non-reactive in fresh human and rat whole blood and does not covalently bond to any of the mid-level abundance human plasma proteins. CNX-774 demonstrates potent inhibitory activity towards the intended target, Btk, while achieving remarkable specificity in a variety of assays designed to assess off-target reactivity towards abundant cellular thiols and blood proteins |
| 參考文獻： |
1. Matthew Labenski, et al. In Vitro Reactivity Assessment of Covalent Drugs Targeting Bruton's Tyrosine Kinase. 2. Akintunde Akinleye, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013 Aug 19;6:59. |
| 溶解性： |
DMSO : ≥ 45 mg/mL (90.09 mM) |
| 保存條件： |
2-8℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.002 ml |
10.01 ml |
20.02 ml |
| 5 mM |
0.4 ml |
2.002 ml |
4.004 ml |
| 10 mM |
0.2 ml |
1.001 ml |
2.002 ml |
| 50 mM |
0.04 ml |
0.2 ml |
0.4 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京